{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel+%28Temsirolimus%29&page=10", "query": { "intervention": "Torisel (Temsirolimus)", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 648, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel+%28Temsirolimus%29&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel+%28Temsirolimus%29&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:58:31.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00061360", "title": "Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia" ], "interventions": [ { "name": "ATG+Rapamune+cyclosporine", "type": "DRUG" }, { "name": "ATG+cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "2 Years to 110 Years" }, "enrollment_count": 77, "start_date": "2003-06-26", "completion_date": "2015-09-08", "has_results": false, "last_update_posted_date": "2021-06-30", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061360" }, { "nct_id": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "EP0062", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ellipses Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 95, "start_date": "2023-01-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573126" }, { "nct_id": "NCT01008917", "title": "Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "sorafenib with temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-11-17", "completion_date": "2013-06-27", "has_results": false, "last_update_posted_date": "2019-05-09", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 2, "location_summary": "San Francisco, California • Chicago, Illinois", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008917" }, { "nct_id": "NCT01369082", "title": "Extended Follow-Up After Islet Transplantation in T1D", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 1 Diabetes (T1D)", "Islet Transplantation" ], "interventions": [ { "name": "Maintenance Immunosuppressive Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2011-05", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 8, "location_summary": "San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369082" }, { "nct_id": "NCT03253913", "title": "Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphangioleiomyomatosis" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Resveratrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2018-03-31", "completion_date": "2022-10-15", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03253913" }, { "nct_id": "NCT00533442", "title": "Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 170, "start_date": "2000-09", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-12", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533442" }, { "nct_id": "NCT04433572", "title": "Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease", "Critical Limb Ischemia" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Saline placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mercator MedSystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-07-30", "completion_date": "2032-08-01", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 2, "location_summary": "Houma, Louisiana • Dallas, Texas", "locations": [ { "city": "Houma", "state": "Louisiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04433572" }, { "nct_id": "NCT05896839", "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Basal Cell Carcinoma", "Metastatic Carcinoma in the Skin", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Unresectable Basal Cell Carcinoma", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-07-24", "completion_date": "2027-08-02", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896839" }, { "nct_id": "NCT02588339", "title": "Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "GVHD" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-03-04", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588339" }, { "nct_id": "NCT04339101", "title": "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Hematologic and Lymphocytic Disorder", "Myelodysplastic Syndrome", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Itacitinib Adipate", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 59, "start_date": "2020-11-05", "completion_date": "2025-10-09", "has_results": true, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T10:58:31.714Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339101" } ] }